Alendronate remains NICE choice for osteoporosis
This article was originally published in Scrip
The most recent version of detailed draft guidance for the health service in England and Wales continues to recommend generic alendronate as a first choice for the primary and secondary prevention of osteoporotic fragility fractures in postmenopausal women, but the long history of this appraisal suggests that the National Institute for health and Clinical Excellence(NICE) may have bitten off more than can easily be chewed in one sitting.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.